Ferenc Zádor

发表

Recent Molecular Insights into Agonist-specific Binding to the Mu-Opioid Receptor

K. Király, F. Zádor, M. Al-Khrasani, 2022, Frontiers in Molecular Biosciences.

Novel cyclic biphalin analogue with improved antinociceptive properties.

E. Novellino, V. Hruby, A. Mollica, 2014, ACS medicinal chemistry letters.

Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions

L. Vécsei, G. Horváth, G. Kékesi, 2019, Molecules.

Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression

L. Vécsei, S. Dvorácskó, C. Tömböly, 2021, International journal of molecular sciences.

Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates

E. Novellino, S. Carradori, A. Mollica, 2016, Journal of enzyme inhibition and medicinal chemistry.

Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner

P. Klivényi, L. Vécsei, G. Nagy, 2015, Neuropharmacology.

Low dosage of rimonabant leads to anxiolytic like behavior in a cannabinoid receptor independent manner via inhibiting expression levels and G-protein activity of kappa opioid receptors

P. Klivényi, L. Vécsei, G. Nagy, 2015 .

Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors

A. Zimmer, F. Ötvös, S. Benyhe, 2012, Neurochemistry International.

Comparisons of In Vivo and In Vitro Opioid Effects of Newly Synthesized 14-Methoxycodeine-6-O-sulfate and Codeine-6-O-sulfate

Z. Zádori, A. Váradi, S. Hosztafi, 2020, Molecules.

Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine

Á. Párdutz, L. Vécsei, S. Dvorácskó, 2017, International journal of molecular sciences.

Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav2.2 Blocker Multitarget Ligands

E. Novellino, A. Mollica, I. Vetter, 2015, Chemical biology & drug design.

Efficacy-Based Perspective to Overcome Reduced Opioid Analgesia of Advanced Painful Diabetic Neuropathy in Rats

Z. Zádori, S. Mousa, M. Schäfer, 2019, Front. Pharmacol..

Receptome: Interactions between three pain-related receptors or the "Triumvirate" of cannabinoid, opioid and TRPV1 receptors.

M. Wollemann, F. Zádor, Ferenc Zádor, 2015, Pharmacological research.

On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance

Z. Zádori, M. Spetea, H. Schmidhammer, 2020, Molecules.

Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists

A. Mollica, L. Vécsei, G. Zengin, 2020, Biomolecules.

Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine

A. Bojarski, W. Solecki, R. Przewłocki, 2019, British journal of pharmacology.

Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors

E. Novellino, A. Mollica, R. Silvestri, 2017, Journal of enzyme inhibition and medicinal chemistry.

Shedding Light on the Pharmacological Interactions between μ-Opioid Analgesics and Angiotensin Receptor Modulators: A New Option for Treating Chronic Pain

T. Tábi, Z. Zádori, É. Szökő, 2021, Molecules.

The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats

Z. Zádori, S. Mousa, M. Schäfer, 2018, Neurochemical Research.

Biochemistry of opioid (morphine) receptors: binding, structure and molecular modelling

F. Ötvös, S. Benyhe, F. Zádor, 2015 .

Long-term systemic administration of kynurenic acid brain region specifically elevates the abundance of functional CB1 receptors in rats

Á. Párdutz, L. Vécsei, A. Borsodi, 2020, Neurochemistry International.

14‐O‐Methylmorphine: A Novel Selective Mu‐Opioid Receptor Agonist with High Efficacy and Affinity

Z. Zádori, A. Váradi, S. Hosztafi, 2017, European journal of pharmacology.

Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity

A. Borsodi, S. Benyhe, F. Zádor, 2014, Neurochemistry International.

Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model

L. Hársing, T. Tábi, Z. Zádori, 2021, International journal of molecular sciences.

Glycine Transporter 1 Inhibitors: Predictions on Their Possible Mechanisms in the Development of Opioid Analgesic Tolerance

M. Al-Khrasani, A. R. Galambos, Ferenc Zádor, 2024, Biomedicines.

Biochemical and pharmacological characterization of three opioid-nociceptin hybrid peptide ligands reveals substantially differing modes of their actions

A. Magyar, A. Perczel, G. Garab, 2018, Peptides.

Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.

A. Mollica, A. Stefanucci, G. Macedonio, 2019, European journal of medicinal chemistry.

Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis

K. Király, M. Al-Khrasani, Nariman Essmat, 2023, Molecules.

R-Baclofen Treatment Corrects Autistic-like Behavioral Deficits in the RjIbm(m):FH Fawn-Hooded Rat Strain

R. Kedves, Ferenc Zádor, Balázs Lendvai, 2024, Pharmaceuticals.